[go: up one dir, main page]

MX2022015581A - 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. - Google Patents

2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.

Info

Publication number
MX2022015581A
MX2022015581A MX2022015581A MX2022015581A MX2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A MX 2022015581 A MX2022015581 A MX 2022015581A
Authority
MX
Mexico
Prior art keywords
sub
disorders
inhibitors
prevention
management
Prior art date
Application number
MX2022015581A
Other languages
English (en)
Inventor
Hong Liu
Jian Liu
Ashok Arasappan
Jason M Cox
Ian M Bell
Christopher S Burgey
Mark E Layton
James J Perkins
Zhe Wu
Iii Michael J Kelly
Akshay A Shah
Christopher James Bungard
Michael David Vanheyst
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022015581A publication Critical patent/MX2022015581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Nuevos compuestos de la fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de la actividad de los canales Nav1.8 y pueden ser útiles en el tratamiento, prevención, gestión, mejoría, control y supresión de enfermedades mediadas por la actividad de los canales Nav1.8. Los compuestos de la presente invención pueden ser útiles en el tratamiento, prevención o gestión de trastornos de dolor, trastornos de tos, trastornos de picazón aguda y trastornos de picazón crónica. (ver Fórmula).
MX2022015581A 2020-06-17 2021-06-15 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. MX2022015581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040461P 2020-06-17 2020-06-17
PCT/US2021/037303 WO2021257490A1 (en) 2020-06-17 2021-06-15 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015581A true MX2022015581A (es) 2023-01-24

Family

ID=76829646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015581A MX2022015581A (es) 2020-06-17 2021-06-15 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.

Country Status (22)

Country Link
US (2) US11802122B2 (es)
EP (1) EP4168393A1 (es)
JP (3) JP7323723B2 (es)
KR (1) KR20230024985A (es)
CN (1) CN116134018A (es)
AR (1) AR122628A1 (es)
AU (1) AU2021293176A1 (es)
BR (1) BR112022025805A2 (es)
CA (1) CA3182633A1 (es)
CL (1) CL2022003544A1 (es)
CO (1) CO2022018295A2 (es)
CR (1) CR20220642A (es)
DO (1) DOP2022000290A (es)
EC (1) ECSP23003443A (es)
GE (1) GEP20257750B (es)
IL (1) IL299180A (es)
MX (1) MX2022015581A (es)
PE (1) PE20231383A1 (es)
SA (1) SA522441741B1 (es)
TW (1) TWI806073B (es)
WO (1) WO2021257490A1 (es)
ZA (1) ZA202213566B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299180A (en) * 2020-06-17 2023-02-01 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2024519487A (ja) * 2021-05-07 2024-05-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類
CR20230519A (es) * 2021-05-07 2024-01-19 Merck Sharp & Dohme Llc Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
PE20251179A1 (es) 2022-04-22 2025-04-23 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CR20240512A (es) 2022-04-25 2025-03-03 Siteone Therapeutics Inc Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
CN116444551A (zh) * 2023-04-21 2023-07-18 遵义医科大学 一种利用可见光诱导脱羧交叉偶联反应合成二级三氟甲基硼酸酯的方法
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
AU2008234855B2 (en) 2007-04-03 2011-01-20 Glaxo Group Limited Imidazolidine carboxamide derivatives as P2X7 modulators
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
AU2008310660A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
KR20100075631A (ko) 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
AU2012272895B2 (en) 2011-06-24 2015-01-22 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
AR095192A1 (es) 2013-01-31 2015-09-30 Vertex Pharma Quinolina y quinazolinamidas como modulares de canales de sodio
US9108903B2 (en) 2013-01-31 2015-08-18 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
PL3239134T3 (pl) 2013-01-31 2021-06-14 Vertex Pharmaceuticals Incorporated Pirydonoamidy jako modulatory kanałów sodowych
WO2014146111A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
AP2016009023A0 (en) 2013-07-19 2016-02-29 Vertex Pharma Sulfonamides as modulators of sodium channels
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
WO2017209322A1 (ko) 2016-05-31 2017-12-07 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
UA124857C2 (uk) 2017-05-16 2021-12-01 Вертекс Фармасьютикалз Інкорпорейтед Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
EA202090688A1 (ru) * 2017-09-13 2020-07-06 Эмджен Инк. Бис-амидные соединения, активирующие саркомер, и варианты их применения
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL299180A (en) * 2020-06-17 2023-02-01 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors

Also Published As

Publication number Publication date
US20210403457A1 (en) 2021-12-30
TWI806073B (zh) 2023-06-21
ZA202213566B (en) 2024-07-31
CA3182633A1 (en) 2021-12-23
GEP20257750B (en) 2025-03-25
IL299180A (en) 2023-02-01
ECSP23003443A (es) 2023-02-28
WO2021257490A1 (en) 2021-12-23
JP2023524167A (ja) 2023-06-08
US11802122B2 (en) 2023-10-31
BR112022025805A2 (pt) 2023-01-10
JP2023093623A (ja) 2023-07-04
CN116134018A (zh) 2023-05-16
CL2022003544A1 (es) 2023-06-02
JP7323723B2 (ja) 2023-08-08
JP7575518B2 (ja) 2024-10-29
AU2021293176A1 (en) 2023-02-02
KR20230024985A (ko) 2023-02-21
CR20220642A (es) 2023-02-15
SA522441741B1 (ar) 2024-03-03
JP2023139235A (ja) 2023-10-03
US20230312528A1 (en) 2023-10-05
EP4168393A1 (en) 2023-04-26
DOP2022000290A (es) 2023-01-31
AR122628A1 (es) 2022-09-21
CO2022018295A2 (es) 2022-12-20
PE20231383A1 (es) 2023-09-12
TW202214573A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
MX2022015581A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.
MX2022015580A (es) 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
MX2022015579A (es) 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.
ZA202102628B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MX2023013146A (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
MX2023013147A (es) Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
PH12021552134A1 (en) Pyrazine derivative and application thereof in inhibiting shp2
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2024000043A (es) Compuestos inhibidores de la caspasa-2.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
MX2024015496A (es) Compuestos de pirimidina que contienen boro, composiciones que los contienen, metodos y usos de los mismos
WO2023122185A3 (en) Regulation of lipid dyshomeostasis for prophylaxis or amelioration of neurodegeneration
WO2024006379A8 (en) Methods and compounds for inhibiting mkk7 enzymes